期刊文献+

唑来膦酸治疗恶性肿瘤骨转移性疼痛85例的临床观察 被引量:6

A Clinical Study of Zoledronic Acid in Pain Relief for Patients with Metastatic Bone Tumors
下载PDF
导出
摘要 目的观察唑来膦酸治疗恶性肿瘤骨转移性疼痛的疗效及不良反应。方法85例恶性肿瘤骨转移疼痛的患者每次予唑来膦酸4mg,加入100ml生理盐水中静脉滴注,滴注时间大于15min,每4周1次,至少连续2次。结果止疼效果:完全缓解15例(17.6%),明显缓解24例(28.2%),中度缓解30例(35.3%),轻度缓解16例(18.8%),中位起效缓解时间为第3天,平均缓解时间28天。主要不良反应为发热,消化道反应,短暂性疼痛加剧,肌酐水平轻度升高,反应轻,无需特殊处理。结论唑来膦酸治疗恶性肿瘤骨转移性疼痛镇痛效果较好,持续时间较长,不良反应轻,患者能耐受。 Objective To evaluate the efficacy and toxicities of Zoledronic acid in pain relief for patients with metastatic bone tumors. Methods 85 paticents with metastatic bone tumors were treated with 4 milligram of Zoledronic acid. The treatment was repeated every four weeks. Treatment efficacy and toxicities were evaluated after at least 2 cycles. Results Complete pain re- lief was achieved in 17.6% (15/18) patients, and significant pain relief was achieved in 28.2% (24/85) patients. 35.3% (30/85) patients had moderate pain relief, and 18, 8% (16/85) patients had mild pain relief. The median time to begin the pain relief was 3 days, and the mean time of pain relief was 28days. The main adverse effects included febricity, gastrointestinal reactions, temporal aggravation of the bone pain and slight increase of creatinine level. Conclusion Zoledronic acid treatment is effective in the treatment of metastatic bone tumors with lasting pain relief and minimum toxicities.
出处 《实用癌症杂志》 2008年第3期291-292,共2页 The Practical Journal of Cancer
关键词 唑来膦酸 恶性肿瘤 骨转移性疼痛 Zoledronic acid Malignant tumor Pain of bone metastases
  • 相关文献

参考文献3

  • 1Lipton A , Samll E, Saad F, et al. The new bisphonate, Zometa (Zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparision to pamidronate [J]. Cancer Invest,2001,20( 1 ) : 45.
  • 2Lipton A, Costa L, Ali S, et al. Use of bone turnover for monitoring bone metastases and response to therapy [J]. Seminars in Oncology,2001,28(4) : 254.
  • 3Pataki A, Muller K, Green JR, et al. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on ratbone; a comparative histomorphometric study on the cancellous bone formed before, during and after treatment [J]. Anat Rec, 1997. 249 : 458.

同被引文献33

  • 1金稚奎.骨转移瘤的放射性核素治疗[J].国外医学(放射医学核医学分册),1995,19(4):145-148. 被引量:46
  • 2张雨洁,赵锦艳.唑来膦酸钠治疗癌症骨转移引起疼痛的疗效观察[J].中国实用医刊,2010,37(17):84-85. 被引量:2
  • 3宋小莲,白冲.肺癌骨转移诊治的研究进展[J].中国癌症杂志,2005,15(6):583-587. 被引量:9
  • 4Arimidex,Tamoxifen,Alone or in Combination(ATAC)Trialists',Group,Forbes JF,Cuzick J,et al.Effect of anastrozolc and tamoxi-fen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAG trial[J].Lancet Oncol,2008,9(1):45-53.
  • 5Crivellari D,Sun Z,Coates AS,et al.Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:the BIG 1-98 trial[J].J Clin Oncol,2008,26(12):1972-1979.
  • 6Kanis JA.Assessment of fracture risk and its application to screen-ing for Postmenopausal osteoporosis.:synopsis of a WHO report.WHO Study Group[J].Osteoporos Int,1994,4(6):368-381.
  • 7Hadji P.Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis[J].Crit Rev Oncol Hematol,2009,69(1):73-82.
  • 8Skerjanec A,Berenson J,Hsu C,et al.The pharmacokinetics and pharmacodynemics of zoledronic acid in cancer patients with vary-ing degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
  • 9Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic ac-id for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
  • 10Diel IJ,Bergner R Grotz KA.Adverse effects of bisphosphonates:current issues[J]:J Support Oncol,2007,5(10):475-482.

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部